Please assess the completion status of the following clinical trial:

Trial Title: InterLeukin-7 to Improve Clinical Outcomes in Lymphopenic pAtients With COVID-19 Infection ( ILIAD-7-US-I )

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. A written, signed informed consent, or emergency oral consent, by the patient or the patient's legally authorized representative, and the anticipated ability for participant to be re-consented in the future for ongoing Study participation~2. Men and women aged ≥ 25 - 80 (included) years of age~3. Hospitalized patients with two absolute lymphocyte count (ALC) ≤ 1000 cells/mm3, at two time points at least 24 hours apart, following HOSPITALIZATION:~4. Hospitalized patients with moderate to severe hypoxemia requiring oxygen therapy at \>4L per minute nasal cannula or greater to keep saturations \>90%, non-invasive positive pressure ventilation (e.g., BIPAP), or patients intubated / ventilated for respiratory failure~5. Confirmed infection with COVID-19 by any acceptable test available / utilized at each site~6. Willingness and ability to practice contraception regardless of the gender of the patient during 5 month after last drug exposure~7. Private insurance or government / institution financial support (through CMS or other)~Exclusion Criteria:~1. Pregnancy or breast feeding~2. ALT and/or AST \> 5 x ULN~3. Known, active auto-immune disease;~4. Ongoing cancer treatment with chemotherapy / immunotherapy or any cancer therapy within last 3 months and/or ongoing~5. Patients with past history of Solid Organ transplant~6. Active tuberculosis, uncontrolled active HBV or HCV infection, HIV with positive viral load~7. Hospitalized patients with refractory hypoxia, defined as inability to maintain saturation \>85% with maximal available therapy for \>6 hours~8. Patients receiving any agent with immune suppressive effects, other than steroids at dosages less than 300 mg/day equivalent hydrocortisone and/or anti-IL-6R treatments like Tocilizumab or Sarilumab or anti-IL-1 treatment like Anakinra which should preferably be minimized~9. Patients with baseline Rockwood Clinical Frailty Scale ≥ 6 at Hospital admission~10. Patients showing an increase of the NEWS2 score by more than 6 points during the screening/ baseline period (48 to 72 hrs prior to first administration)~11. Patients under guardianship

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CYT107 Treatment (Type: EXPERIMENTAL): Intramuscular (IM) administration of CYT107 twice a week for 3 weeks
- Placebo (Type: PLACEBO_COMPARATOR): Intramuscular (IM) administration of Saline twice a week for 3 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).